| 產(chǎn)品編號(hào) | bs-3065R-PE |
| 英文名稱 | Rabbit Anti-Phospho-CD19 (Tyr531)/PE Conjugated antibody |
| 中文名稱 | PE標(biāo)記的磷酸化CD19抗體 |
| 別 名 | Antibody deficiency due to defect in CD19, included; AW495831; B lymphocyte antigen CD19; B lymphocyte surface antigen B4; B4; CD 19; CD19 antigen; CD19 molecule; Cd19 protein; Differentiation Antigen CD19; Leu 12; Leu12; Lymphocyte Surface Antigen; MGC109570; MGC12802; T-cell surface antigen Leu-12. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 產(chǎn)品類型 | 磷酸化抗體 |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞表面分子 b-淋巴細(xì)胞 |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, (predicted: Mouse, Rat, Dog, Pig, Cow, Rabbit, Guinea Pig, ) |
| 產(chǎn)品應(yīng)用 | Flow-Cyt=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 59kDa |
| 細(xì)胞定位 | 細(xì)胞膜 |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated Synthesised phosphopeptide derived from human CD19 around the phosphorylation site of Tyr531 [DS(p-Y)EN] |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: CD19 is a transmembrane glycoprotein that is delectively expressed on the cell surface of B-lymphocytes,where it activates intracellular signaling cascades involving both Ras and phosphatidylinositol 3-kinase pathways.Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Function: Assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Subunit: Forms a complex with CD21, CD81 and CD225 in the membrane of mature B-cells. Interacts with VAV. Interacts with GRB2 and SOS when phosphorylated on Tyr-348 and/or Tyr-378. Interacts with PLCG2 when phosphorylated on Tyr-409. Interacts with LYN. Subcellular Location: Membrane; Single-pass type I membrane protein. Post-translational modifications: Phosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation. Phosphorylated on tyrosine residues by LYN. DISEASE: Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low. Similarity: Contains 2 Ig-like C2-type (immunoglobulin-like) domains. Database links: Entrez Gene: 930 Human Entrez Gene: 12478 Mouse Omim: 107265 Human SwissProt: P15391 Human SwissProt: P25918 Mouse Unigene: 652262 Human Unigene: 4360 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. CD19是一種質(zhì)膜蛋白質(zhì)，參與信號(hào)傳導(dǎo)作用。表達(dá)與前B細(xì)胞和成熟的B細(xì)胞膜表面，與B細(xì)胞的活化調(diào)節(jié)和發(fā)育調(diào)節(jié)相關(guān)，在T細(xì)胞和正常粒細(xì)胞上無(wú)表達(dá)。此抗體可以特異性識(shí)別CD19，主要用于標(biāo)記正常B細(xì)胞及腫瘤性B細(xì)胞。 |
